What happened
On April 1, 2026 the FDA approved Foundayo (orforglipron) for adults with obesity, or with overweight plus at least one weight-related condition, used with a lower-calorie diet and more activity. The agency called it the first new molecular entity under the Commissioner's National Priority Voucher pilot and the fastest such approval since 2002. The decision came 50 days after filing, months ahead of a January 20, 2027 PDUFA date.
Foundayo is a once-daily tablet. The FDA label starts at 0.8 mg, then steps to 2.5 mg and 5.5 mg after at least 30 days each. Later steps are 9 mg, 14.5 mg, and 17.2 mg if response and tolerability allow. Acting CDER director Tracy Beth Hoeg said the pill is a GLP-1 receptor partial agonist that does not have to be taken on an empty stomach.
Two randomized studies versus dummy pills, in adults who had obesity or who had extra weight plus another condition, supported approval. After 72 weeks the treated groups lost more weight than placebo. The FDA lists gut effects, headache, fatigue, hair loss, and warnings that include pancreatitis, severe gut reactions, kidney injury from volume loss, low blood sugar, gallbladder disease, diabetic eye disease, and lung contents entering the airway during general anesthesia or heavy sedation. It should not be combined with another GLP-1. The boxed warning about thyroid C-cell tumors remains.
What it means
People who want a pill instead of a shot now have a second FDA-approved oral option beside Wegovy tablets. Foundayo is a different molecule, with different food timing. A clinician still has to decide whether any GLP-1 is appropriate, which product to use, and how to titrate it.
NPR reported the same day that Lilly's cash starting dose is $149 a month and that a list price for insurance negotiation was not yet posted. That is secondary coverage, not an FDA pricing decision, and it can change.
What it does not mean
The FDA notice does not rank Foundayo against Wegovy tablets, Wegovy shots, Zepbound, or surgery. There is no head-to-head trial in the approval package. It is not a reason to start, stop, or stack products without a clinician. It is not a compounding pathway.
Sources
- 1. FDA, April 1, 2026 Foundayo (orforglipron) approval
- 2. NPR, April 1, 2026 secondary report on the pill and cash start price
Related guide
GLP-1 medications Information Center hub
Related discussion
GLP-1 Weight Loss Medications forum
Educational information only. Not medical advice. Do not start, stop, or change treatment from this brief.